Kenneth R Chapman1, Ekkehard Beck2, Daniel Alcaide3, Esther Garcia Gil4,2. 1. Asthma and Airway Centre, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada. 2. Institut für Gesundheitsförderung GmbH, Rüdersdorf, Germany. 3. R and D Centre, Almirall S.A., Barcelona, Spain. 4. R and D Centre, AstraZeneca PLC, Barcelona, Spain.
Abstract
Background: Aclidinium bromide, an M3-receptor-selective, twice-daily (BID), long-acting muscarinic antagonist, is rapidly hydrolyzed in human plasma, resulting in low systemic exposure and urinary excretion. We evaluated the overall and cardiovascular (CV) safety of aclidinium in patients with moderate to severe chronic obstructive pulmonary disease (COPD) by pooling data from 6 randomized, double-blind, placebo-controlled, parallel-group studies of ≥1 month's duration. METHODS:Patients were current/former smokers aged ≥40 years with no history of clinically significant CV conditions. Treatment was administered (morning and evening) via GenuairTM/Pressair.®a Adverse events (AEs), major adverse CV events (MACE), cardiac and cerebrovascular AEs, and serious AEs (SAEs) were analyzed. Results: The pooled population included 2781 patients (aclidinium: n=1529; placebo: n=1252). The incidence of AEs was similar with aclidinium (53.5%) and placebo (55.4%), as was the incidence of cardiac (aclidinium: 5.0%; placebo: 4.4%) and cerebrovascular (aclidinium: 0.4%; placebo: 0.5%) events. The incidence of MACE was low (AEs: 0.7%; SAEs: 0.5%) and comparable between groups. The incidence of cardiac and cerebrovascular events was similar for patients with CV risk factors with aclidinium andplacebo (rate ratio [RR] [95 %confidence interval (CI)]=1.01[.074, 1.39]). In patients with mild to severe renal impairment, the incidence of cardiac events was similar between groups (RR [95% CI]=0.87 [0.56, 1.36]). Conclusion:Aclidinium 400µg BID has a good safety profile and this pooled analysis found no evidence of increased CV or cerebrovascular risk compared with placebo in patients with moderate to severe COPD. Further studies are needed in high-risk patients.
RCT Entities:
Background: Aclidinium bromide, an M3-receptor-selective, twice-daily (BID), long-acting muscarinic antagonist, is rapidly hydrolyzed in human plasma, resulting in low systemic exposure and urinary excretion. We evaluated the overall and cardiovascular (CV) safety of aclidinium in patients with moderate to severe chronic obstructive pulmonary disease (COPD) by pooling data from 6 randomized, double-blind, placebo-controlled, parallel-group studies of ≥1 month's duration. METHODS:Patients were current/former smokers aged ≥40 years with no history of clinically significant CV conditions. Treatment was administered (morning and evening) via GenuairTM/Pressair.®a Adverse events (AEs), major adverse CV events (MACE), cardiac and cerebrovascular AEs, and serious AEs (SAEs) were analyzed. Results: The pooled population included 2781 patients (aclidinium: n=1529; placebo: n=1252). The incidence of AEs was similar with aclidinium (53.5%) and placebo (55.4%), as was the incidence of cardiac (aclidinium: 5.0%; placebo: 4.4%) and cerebrovascular (aclidinium: 0.4%; placebo: 0.5%) events. The incidence of MACE was low (AEs: 0.7%; SAEs: 0.5%) and comparable between groups. The incidence of cardiac and cerebrovascular events was similar for patients with CV risk factors with aclidinium and placebo (rate ratio [RR] [95 %confidence interval (CI)]=1.01[.074, 1.39]). In patients with mild to severe renal impairment, the incidence of cardiac events was similar between groups (RR [95% CI]=0.87 [0.56, 1.36]). Conclusion:Aclidinium 400µg BID has a good safety profile and this pooled analysis found no evidence of increased CV or cerebrovascular risk compared with placebo in patients with moderate to severe COPD. Further studies are needed in high-risk patients.
Authors: Paul W Jones; Dave Singh; Eric D Bateman; Alvar Agusti; Rosa Lamarca; Gonzalo de Miquel; Rosa Segarra; Cynthia Caracta; Esther Garcia Gil Journal: Eur Respir J Date: 2012-03-22 Impact factor: 16.671
Authors: Miguel Divo; Claudia Cote; Juan P de Torres; Ciro Casanova; Jose M Marin; Victor Pinto-Plata; Javier Zulueta; Carlos Cabrera; Jorge Zagaceta; Gary Hunninghake; Bartolome Celli Journal: Am J Respir Crit Care Med Date: 2012-05-03 Impact factor: 21.405
Authors: Bartolome Celli; Marc Decramer; Steven Kesten; Dacheng Liu; Sunil Mehra; Donald P Tashkin Journal: Am J Respir Crit Care Med Date: 2009-09-03 Impact factor: 21.405
Authors: Robert A Wise; Kenneth R Chapman; Benjamin M Scirica; David A Schoenfeld; Deepak L Bhatt; Sami Z Daoud; Beatriz Seoane; Colin Reisner; Esther Garcia Gil Journal: Chronic Obstr Pulm Dis Date: 2018-01-24
Authors: Robert A Wise; Kenneth R Chapman; Benjamin M Scirica; Deepak L Bhatt; Sami Z Daoud; Sofia Zetterstrand; Colin Reisner; Esther Garcia Gil Journal: JAMA Date: 2019-05-07 Impact factor: 56.272
Authors: Jaclyn A Smith; Lorcan McGarvey; Alyn H Morice; Surinder S Birring; Jadwiga A Wedzicha; Massimo Notari; Antonio Zapata; Rosa Segarra; Beatriz Seoane; Diana Jarreta Journal: Am J Respir Crit Care Med Date: 2019-09-01 Impact factor: 21.405